- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
2 reports, 2 independent
Updated Aug 28
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jay S. Duker referenced findings from the Lugano clinical trial on October 19, 2026.Sub-event
EyePoint's clinical trials failed to meet primary endpoints.1 source
EyePoint Pharmaceuticals is developing its LUCIA trial program in alignment with the FDA.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- OKYO Pharma is conducting clinical trials in Europe and Italy while seeking FDA approval for its investigational therapy.
- The FDA identified deficiencies in a drug application submitted by Aquestive Therapeutics, Inc.
Coverage
Newest first; wire copies grouped- prnewswire.com
- GlobeNewswireEyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration – LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, d